Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kai Wucherpfennig, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Kai Wucherpfennig and Yoshinaga Ito.
Connection Strength

2.152
  1. Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity. J Exp Med. 2018 10 01; 215(10):2617-2635.
    View in: PubMed
    Score: 0.806
  2. CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells. Cancer Discov. 2021 Aug; 11(8):2050-2071.
    View in: PubMed
    Score: 0.240
  3. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26.
    View in: PubMed
    Score: 0.239
  4. Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. J Exp Med. 2020 07 06; 217(7).
    View in: PubMed
    Score: 0.229
  5. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells. Cancer Immunol Res. 2020 06; 8(6):769-780.
    View in: PubMed
    Score: 0.224
  6. Discovery of specialized NK cell populations infiltrating human melanoma metastases. JCI Insight. 2019 12 05; 4(23).
    View in: PubMed
    Score: 0.220
  7. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 2018 Mar 30; 359(6383):1537-1542.
    View in: PubMed
    Score: 0.195
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.